Malaysia Nuclear Medicines Market by Type, Modality, Application, and End User : Opportunity Analysis and Industry Forecast, 2020–2028

Malaysia Nuclear Medicines Market by Type, Modality, Application, and End User : Opportunity Analysis and Industry Forecast, 2020–2028

  • June 2021 •
  • 139 pages •
  • Report ID: 6126632 •
  • Format: PDF
Malaysia Nuclear Medicines Market by Type (Diagnostics, Therapeutics, and Biochemistry Research), Modality (SPECT, PET, Beta Emitters, Alpha Emitters, Brachytherapy and Others), Application (Oncology, Cardiology, Thyroid, Neurology, and Others), and End User (Hospitals & Diagnostic Centers, and Research Institutes): Opportunity Analysis and Industry Forecast, 2020–2028

The Malaysia nuclear medicine market was valued at $33.68 million in 2020, and is projected to reach $70.24 million by 2028, registering a CAGR of 9.86% from 2021 to 2028.
Radiopharmaceuticals are pharmaceutical formulations comprise radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance used in the treatment of cancer and cardiac & neurological disorders. Moreover, nuclear medicines of modality, SPECT and PET work as a convenient and safer alternative for patients as compared to X-Rays and other external radiation imaging devices. Applications such as lymphoma and bone metastasis use radiopharmaceuticals, also known as nuclear medicines. F-18, Tc-99, Ga-67, and I-123 are some of the nuclear medicines used in diagnostic procedures, while I-131, Ir192, Y-90, I-125, Lu-177, and Ra-223 are used in therapeutics procedure. More convenient therapeutic radiopharmaceuticals for oncology and cancer treatment replace the conventional chemotherapy methods to open up new avenues in the radiopharmaceuticals market.

The market is currently in its growth stage driven by increase in the number of cancer cases in the Malaysian country and the surge in awareness about nuclear medicine. Convenience of treatment with minimally invasive techniques attracts more patients toward the radiopharmaceuticals mode of treatment as compared to chemotherapy. The factors that drive the radiopharmaceuticals industry include increase in incidence of cardiac patients and adoption of clear imaging techniques such as SPECT and PET in Malaysia, with the help of diagnostic equipment.
The factors that hinder the growth of the market include supply shortages, logistical difficulties, stringent regulations related to the use of nuclear medicine and limited number of trained medical personnel.

The Malaysia nuclear medicine market is segmented into type, modality, application and end user. On the basis of type the market is divided into diagnostics, therapeutics, and biochemistry research. Based on modality the market is segmented into, SPECT, PET, beta emitters, alpha emitters, brachytherapy and others. Furthermore, SPECT is divided into Technetium 99m, Chromium-51, Gallium-67 and others. In addition PET is further divided into Fluorine 18, Gallium-68, and others. On the basis of application, the market is segmented into oncology, cardiology, thyroid, neurology and others. Based on end user, market is categorized into hospitals & diagnostic centers and research institutes

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2020 to 2028, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of factors that drive and restrain the growth of the market is provided.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type
• Diagnostics
• Therapeutics
• Biochemistry Research

By Modality
• SPECT
o Technetium 99m
o Chromium-51
o Gallium-67
o Others
• PET
o Fluorine 18
o Gallium-68
o Others
• Beta emitters
• Alpha emitters
• Brachytherapy
• Others

By Application
• Oncology
• Cardiology
• Thyroid
• Neurology
• Others

By End User
• Hospitals and Diagnostic Centers
• Research Institutes

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Cardinal Health, Inc.
• Fujifilm Holdings Corporation (Irvine Scientific Sales Company, Inc.)
• GE Healthcare,
• Ion Beam Applications (Ion Beam Applications, SA)
• Lantheus Holdings, Inc. (Lantheus Medical Imaging, Inc.)
• MERCK KGAA (Sigma Aldrich)
• Novartis AG (Advanced Accelerator Applications S.A.)
• Otsuka Holding Co., Ltd. (ABX advanced biochemical compounds GmbH)
• Siemens Healthcare GmbH
• Taiyo Nippon Sanso Corporation (Mitsubishi Chemical Holdings Corp)